Moreover, the Cancer Genome Atlas Research Network reported the results of genomes from 200 AML patients and defined 11 genes were mutated in AML with different functional categories.8 Other genomic studies revealed that gene mutations in DNMT3A, ASXL1, and TET2 play essential roles in clonal expansion of pre-leukemic hematopoietic stem cells, and might be related with the relapse.9–11 These gene mutations are the primary therapeutic targets for developing new treatment regimens for AML and RAML. Here, ASXL1 is linked to acute myeloid leukemia.